ライフサイエンスコーパス: creatine kinase

1 assessed by cardiac enzymes, troponin I, and creatine kinase.

2 ere modeled in the C terminus of muscle-type creatine kinase.

3 pyruvate kinase muscle isozyme, isoforms of creatine kinase.

4 including fasciculations and elevated serum creatine kinase.

5 pomyosin, myosin or an isoform of the enzyme creatine kinase.

6 d pathology and reduction in levels of serum creatine kinase.

7 ors make neurotransmission less dependent on creatine kinase.

8 ith significant reduction in levels of serum creatine kinase.

9 ansferase [ALT]), alkaline phosphastase, and creatine kinase.

10 ins such as myosin heavy chain fast type and creatine kinase.

11 ficulties, and normal to moderately elevated creatine kinase.

12 aminotransferase, lactate dehydrogenase, and creatine kinase.

13 thesis from OXPHOS, anaerobic glycolysis and creatine kinase.

14 table for bulky ASB9 substrates, such as the creatine kinases.

15 ut preinfarction angina (n=166) by both peak creatine kinase (1094+/-75 IU/L versus 2270+/-102 IU/L;

16 d in 9 healthy men (mean age 27.9 y, SE 3.3; creatine kinase 115 to 859 IU/L, median 358), was associ

17 Exogenous creatine kinase (500 to 4000 IU/L, phosphocreatine 5 mM)

18 e fibers, increased central nuclei, elevated creatine kinase activity and endomysial fibrosis.

19 fat, cold exposure stimulates mitochondrial creatine kinase activity and induces coordinated express

20 further explore the effect of calmodulin on creatine kinase activity and show that it is increased b

21 in which both oxidative phosphorylation and creatine kinase activity are inhibited.

22 imus lumborum and a 5-fold increase in serum creatine kinase activity compared with healthy male litt

23 on and reduced the vascular adenylate kinase/creatine kinase activity ratio essential for the respons

24 l muscle health in mdx mice, reducing plasma creatine kinase activity, an established measure of musc

25 on of inflammatory markers of muscle damage (creatine kinase activity, C-reactive protein, proinflamm

26 f differentiation, demonstrated by increased creatine kinase activity, fusion index and myotube diame

27 e, as evidenced by i) normal levels of serum creatine kinase activity, ii) a lack of Evans blue dye u

28 ontractile function and a reduction in serum creatine kinase activity.

29 d skeletal muscle mass and normalized plasma creatine kinase activity.

30 dependence of infarct size plotting the peak creatine kinase against time onset of ischemia.

31 lar to enolase, pyruvate kinase, isoforms of creatine kinase, aldolase A and an isoform of glyceralde

32 ne blood chemistry was normal, as were serum creatine kinase and aldolase levels and thyroid, hepatic

33 ngs to the phosphagen kinase family of which creatine kinase and arginine kinase are the typical repr

34 We also found that plasma creatine kinase and aspartate aminotransferase levels in

35 Maximum creatine kinase and creatine kinase-MB values declined (

36 boratory analysis showed alteration of serum creatine kinase and creatinine in the Leu389Ser ALS4 coh

37 e cell number, and a decrease in activity of creatine kinase and several oxidative enzymes.

38 ult onset muscular dystrophy with high serum creatine kinase and that mutation screening, particularl

39 rast-enhanced cardiac MRI (CMRI; day 3+/-1), creatine kinase and troponin I area-under-the-curve, and

40 Apart from transient elevations of creatine kinase and troponin, microemboli can be visuali

41 revascularization report reduced release of creatine kinase and troponin.

42 Of the 1,800 patients enrolled, 1,652 with creatine kinase and/or creatine kinase-myocardial band (

43 ased lactate dehydrogenase, pyruvate kinase, creatine kinase, and cytochrome c oxidase activities, an

44 derived from lactate dehydrogenase, one from creatine kinase, and four from serum albumin protein.

45 f three model proteins (Human Serum Albumin, creatine kinase, and myoglobin).

46 ge, sex, and admission levels of troponin I, creatine kinase, and N-terminal pro-brain natriuretic pe

47 size distribution, centralized nuclei, serum creatine kinase, and quantitative histopathology scores.

48 f such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke di

49 5 IU/L versus 2270+/-102 IU/L; P<0.0001) and creatine kinase area under curve (18 420+/-18 941 versus

50 terquartile range, 14-42; P<0.01) and median creatine kinase areas under the curve were 22 000 and 38

51 with serum muscle enzyme levels (P<0.05 for creatine kinase, aspartate aminotransferase, and aldolas

52 variability compared with the commonly used creatine kinase assay, and correlated better with the re

53 y plus rifaximin group showed an increase in creatine kinase at the end of treatment compared with pa

54 inding protein, we identified it to be brain creatine kinase (B-CK).

55 e levels of creatine kinase, MB isoenzyme of creatine kinase, blood urea nitrogen, creatinine, K(+) i

56 sed guanidinoacetate N-methyltransferase and creatine kinase, both at the protein and RNA levels, and

57 gen species (mROS): hexokinases I and II and creatine kinase bound to mitochondrial membranes.

58 These miRNAs convergently target creatine kinase, brain-type (CKB), which phosphorylates

59 ll patients showed increased levels of serum creatine kinase but no or minor muscle weakness.

60 A 43 kDa band, identified as creatine kinase by proteomic analysis, showed the potent

61 ce of isotopically enriched magnesium on the creatine kinase catalyzed phosphorylation of adenosine d

62 ription, and QI 3 = complete blood count and creatine kinase check every 6 months for gout patients r

63 s critical role in hair bundle function, the creatine kinase circuit is essential for high-sensitivit

64 hypothesized that ATP transfer rate through creatine kinase (CK) (k(f)(CKrest)) would be increased,

65 Serial creatine kinase (CK) and CKMB or troponin measurements w

66 We find two major proteins, creatine kinase (CK) and glyceraldehyde-3-phosphate dehy

67 (MI) changed to rely on troponin rather than creatine kinase (CK) and its MB fraction (CK-MB).

68 kinases of known structure (the homodimeric creatine kinase (CK) and the monomeric arginine kinase (

69 s, but, to date, has not been confirmed with creatine kinase (CK) assays.

70 In comparing the level and activity of creatine kinase (CK) between wild-type and MuRF1 Tg(+) h

71 Our results show that routine creatine kinase (CK) blood values, plasma EVs physical c

72 We investigate the hypothesis that reduced creatine kinase (CK) capacity and flux is associated wit

73 utilization networks in response to chronic creatine kinase (CK) deficiency, a hallmark of cardiovas

74 In the 14-day study, serum creatine kinase (CK) dropped by 50%, which was not seen

75 f the absolute level and rate of increase of creatine kinase (CK) elevation after primary percutaneou

76 iated with simvastatin-induced myopathy with creatine kinase (CK) elevation.

77 Creatine kinase (CK) is a commonly used biomarker to ass

78 Creatine kinase (CK) is a member of a family of phosphor

79 n the anti-Jo-1 antibody level and the serum creatine kinase (CK) level, as well as muscle and joint

80 Creatine kinase (CK) levels are increased on dried blood

81 a 2-tiered approach to NBS with screening by creatine kinase (CK) levels in dried blood spots followe

82 Serum creatine kinase (CK) levels were lower (p = 0.025), and

83 In addition, serum creatine kinase (CK) levels within the Oxford CMS cohort

84 Anti-HMGCR levels, creatine kinase (CK) levels, and strength were assessed

85 ovascular death or nonfatal MI, defined as a creatine kinase (CK) MB fraction of at least 100 ng/mL o

86 iation of a recently reported variant in the creatine kinase (CK) muscle gene, CKM Glu83Gly (rs115590

87 ATP production rate constants (k(f)) through creatine kinase (CK) or ATP synthase (ATPase) with 2 spe

88 The creatine kinase (CK) reaction plays a critical role in s

89 Tissue injury was assessed by creatine kinase (CK) released and determination of cell

90 The creatine kinase (CK) system is thought to play an integr

91 lationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial band levels, and ske

92 tions, and measurements of serum cTnT, cTnI, creatine kinase (CK), creatine kinase myocardial band (C

93 Another phosphagen kinase, creatine kinase (CK), is found in sponges, cnidarians, a

94 a showing reduced metabolism through cardiac creatine kinase (CK), the major myocardial energy reserv

95 enosine triphosphate (ATP) synthesis through creatine kinase (CK), the primary myocardial energy rese

96 or decreased intracellular ATP generation by creatine kinase (CK), the prime energy reserve of the he

97 erase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK), which cardiac troponins being the

98 Inhibition of creatine kinase (CK), which increases cytosolic ADP, in

99 Creatine treatment enhanced cell fusion in a creatine kinase (CK)-dependent manner suggesting that AT

100 ATP that is synthesized locally from PCr via creatine kinase (CK).

101 Studies evaluating mortality and creatine kinase (CK-MB), troponin, or both were included

102 ir of high-energy phosphate (HEP) bonds, and creatine kinases (CK) catalyze the transfer of HEP from

103 Myoglobin, creatine-kinase (CK) showed increased levels at the star

104 Gower score, time to run 30 feet, and serum creatine kinase [CK] level) and with nonquantitative MR

105 re we report cryo-EM data for the substrate, creatine kinase (CKB) bound to ASB9-ELOB/C, and for full

106 s, we identified that brain-type cytoplasmic creatine kinase (Ckb) was greatly induced in mature oste

107 identified the ATP-buffering, mitochondrial creatine kinase CKMT1 as necessary for survival of EVI1-

108 The present study identifies creatine kinases (CKs), key metabolic enzymes for rapid

109 e dye uptake into muscle and increased serum creatine kinase compared to the 129T2/SvEmsJ background.

110 he most common adverse event was an elevated creatine kinase concentration to more than ten times the

111 ical and functional changes using the muscle creatine kinase conditional frataxin knockout (KO) mouse

112 Ablation of Vps34 in the heart of muscle creatine kinase-Cre;Vps34(f/f) mice led to cardiomegaly

113 Peak and area under the creatine kinase curve did not differ between both groups

114 mechanical overload, which decreased muscle creatine kinase-driven TEAD-1 transgene expression, and

115 ound that Ckb was the predominant isoform of creatine kinase during osteoclastogenesis.

116 on and the contribution of other isoforms of creatine kinase during RANKL-induced osteoclastogenesis

117 different than control in terms of myalgia, creatine kinase elevation, cancer, and discontinuations

118 , gastrointestinal effects, and asymptomatic creatine kinase elevation.

119 tin at its highest doses was associated with creatine kinase elevations (odds ratio, 4.14; 95% credib

120 00 patients [RD], 2.7; 95% CI, -3.2 to 8.7), creatine kinase elevations (RD, 0.2; 95% CI, -0.6 to 0.9

121 was the forward rate constant (k(f)) of the creatine kinase enzyme in the frontal lobe.

122 Reduced kf of the creatine kinase enzyme is consistent with an abnormality

123 (STOMP) study assessed symptoms and measured creatine kinase, exercise capacity, and muscle strength

124 3 and miR-551a expression, which derepresses creatine kinase expression and allows energy to be captu

125 Creatine kinase expression falls, possibly impairing hig

126 common grade 3-4 adverse events were raised creatine kinase (five [6%] in the 200 mg group vs 19 [13

127 nally, these mice exhibited increased plasma creatine kinase following exhaustive exercise when unfed

128 ne kinase reaction, we have now measured the creatine kinase forward reaction rate constant in BD.

129 We found a significant reduction in creatine kinase forward reaction rate constant in the BD

130 hy control participants at 4T and quantified creatine kinase forward reaction rate constant using (31

131 Creatine kinase from salmon and catfish was detected by

132 ants or isoforms of tropomyosin, arginine or creatine kinase, glyceraldehyde-3-phosphate dehydrogenas

133 R, 2.620; 95% CI, 1.073-6.399; P = .035) and creatine kinase (>800 U/L; OR, 2.328; 95% CI, 1.129-4.80

134 ice exhibited progressive MD, elevated serum creatine kinase, heart dilation, blood vessel irregulari

135 Consistent with this model, inhibition of creatine kinase in avascular retinas blocks synaptic tra

136 on by OXPHOS (vOX), anaerobic glycolysis and creatine kinase in moderate and severe intensity exercis

137 here was a significant increase in mean peak creatine kinase in the oxygen group compared with the no

138 We observed no significant changes in creatine kinase in the simvastatin 20 mg/day plus rifaxi

139 value exceeded 10 times normal, but average creatine kinase increased 20.8+/-141.1 U/L (P<0.0001) wi

140 ant bundle protein; at approximately 0.5 mM, creatine kinase is capable of maintaining high ATP level

141 This concept is applied here to creatine kinase isoenzyme (CK-MB), a cardiac biomarker i

142 stically significant (P = .003) reduction in creatine kinase kf was observed in SZ.

143 resonance-determined myocardial salvage and creatine kinase kinetics.

144 y hearing as demonstrated by hearing loss in creatine kinase knockout mice.

145 common grade >= 3 event was increased blood creatine kinase level (26%).

146 Serum creatine kinase level can be normal or only mildly eleva

147 After exercise, at an endogenous creatine kinase level of 4664, ADP-induced platelet aggr

148 borns for Duchenne muscular dystrophy by the creatine kinase level on dried blood spots.

149 -year history of weight loss and an elevated creatine kinase level up to 4000 U/L.

150 The median creatine kinase level was 5326 U/L.

151 = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 t

152 Infarct size was measured as the peak creatine kinase level, a metric supported in a subgroup

153 ntractures, severe scoliosis, elevated serum creatine kinase level, myopathic electrodiagnostic chang

154 ed lactic acidosis and mild elevation of the creatine kinase level.

155 ecificity had proximal weakness (100%), high creatine kinase levels (mean maximum 10,333 IU/liter), a

156 Decreased serum creatine kinase levels (significant improvement for all

157 d by adult onset muscle weakness, high serum creatine kinase levels and a prominent inflammatory infi

158 cle degeneration, but had no effect on serum creatine kinase levels and muscle strength.

159 , Evans blue dye uptake is reduced and serum creatine kinase levels are lower.

160 These programs used elevated creatine kinase levels in dried blood spots for the init

161 Elevated creatine kinase levels in the neonatal period are the in

162 Myopathy--muscle pain or weakness with blood creatine kinase levels more than ten times the upper lim

163 ociated with an increased incidence of serum creatine kinase levels that were more than 10 times the

164 ' muscle biopsies were dystrophic, and serum creatine kinase levels were 1,050 to 9,200U/l.

165 ntral nucleation, tissue fibrosis, and serum creatine kinase levels were dramatically reduced in Sgcd

166 muscle histology, in vitro muscle force, and creatine kinase levels were measured.

167 Muscle MRI and serum creatine kinase levels were normal.

168 Circulating creatine kinase levels were significantly lower in mice

169 thy characterized by mildly increased plasma creatine kinase levels, a variation in myofibre size and

170 ephaly, severe hypotonia with elevated blood creatine kinase levels, and early fatal outcome.

171 distribution and significantly reduced serum creatine kinase levels, but had limited effect on muscle

172 of Dmdmdx-5Cv mice results in reduced serum creatine kinase levels, improved sarcolemmal integrity,

173 ake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-bo

174 is was associated with greatly reduced serum creatine kinase levels, near-normal histology, and funct

175 ut without an earlier onset, increased serum creatine kinase levels, or decreased muscle strength.

176 lder ages, chronic remodeling and increasing creatine kinase levels.

177 ced interstitial fibrosis and elevated serum creatine kinase levels.

178 was accompanied by a significant decrease in creatine kinase levels.

179 Evans blue dye infiltration and lower serum creatine kinase levels.

180 bdominal pain, and moderately elevated serum creatine kinase levels.

181 diffusing capacity for carbon monoxide, and creatine kinase levels.

182 etermined by muscle histopathology and serum creatine kinase levels.

183 neutral protease calpain activity and plasma creatine kinase levels.

184 e histology, running performance, and plasma creatine kinase levels.

185 not associated with persistent elevations in creatine kinase levels.

186 e disorder associated with elevated neonatal creatine kinase levels.

187 esonance imaging, and through elevated serum creatine kinase levels.

188 globin and somatic cytochrome-C) and others (creatine kinase M, malate dehydrogenase cytosolic, fibri

189 Fractional synthesis rate (FSR) of plasma creatine kinase M-type (CK-M) and carbonic anhydrase 3 (

190 e cell apoptosis and reduced serum levels of creatine kinase M.

191 protein expression of creatine kinase-mt and creatine kinase-m isoforms was significantly reduced in

192 00 fg/ml troponin T, creatine kinase MM, and creatine kinase MB in serum.

193 ved hemodynamics and decreased the levels of creatine kinase, MB isoenzyme of creatine kinase, blood

194 similar or lower in HBOC than HEX pigs, but creatine kinase-MB (but not creatine kinase-MB/creatine

195 Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT)

196 rs including troponin I or T (cTnI or cTnT), creatine kinase-MB (CK-MB), and myoglobin.

197 (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB (CK-MB), and TnI and BNP by CART.

198 MI (PMI(Prot)) required a large elevation of creatine kinase-MB (CK-MB), with identical threshold for

199 similar information as a value of 5x ULN for creatine kinase-MB (hazard ratio, 4.31; 99% confidence i

200 rocedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas t

201 re hemodynamic deterioration, preangiography creatine kinase-MB isoenzyme rise >2 x normal, and time

202 images provided equal performance, and peak creatine kinase-MB levels correlated with MRI infarct si

203 Postprocedural cTnT and creatine kinase-MB mass levels (ULN, 6.7 ng/mL in men an

204 There was no increase in creatine kinase-MB or troponin associated with the adven

205 Troponin-T and creatine kinase-MB peaked at day 1 after procedure (both

206 Maximum creatine kinase and creatine kinase-MB values declined (5.2% and 7.6%; P<0.0

207 43; P=0.003 and hazard ratio per doubling of creatine kinase-MB, 1.30; 95% confidence interval, 1.05-

208 ity C-reactive protein (hs-CRP), Troponin-T, creatine kinase-MB, fibrinogen, and D-Dimer concentratio

209 utcome information as a cutoff of 5x ULN for creatine kinase-MB.

210 n the activity of creatine phosphokinase and creatine kinase-MB.

211 models and included haptoglobin, IL-10, and creatine kinase-MB.

212 an HEX pigs, but creatine kinase-MB (but not creatine kinase-MB/creatine kinase ratio) was higher wit

213 function, and perfusion), injury biomarkers (creatine-kinase-MB and troponin I), and histopathologic

214 Studies using the muscle creatine kinase (MCK) conditional frataxin knockout mous

215 inol-binding protein (hRBP) under the muscle creatine kinase (MCK) promoter (MCKhRBP) with the PKCdel

216 ified a conserved sequence within the Muscle creatine kinase (MCK) promoter that is critical for high

217 gnize the MPEX control element in the Muscle creatine kinase (MCK) promoter.

218 ch nebulin deletion was driven by the muscle creatine kinase (MCK) promotor.

219 ke signaling in this process, we used muscle creatine kinase (MCK)-Cre to disrupt expression of insul

220 omatic gene transfer or transgenesis (muscle creatine kinase [MCK]-EcSOD) in mice significantly atten

221 -activated receptor alpha (PPARalpha; muscle creatine kinase [MCK]-PPARalpha) or PPARbeta/delta (MCK-

222 5:00 am onset of reperfusion, with the peak creatine kinase measured at the peak of the curve being

223 n of total reverse T3, high concentration of creatine kinase, mild anaemia), and radiological (thicke

224 st notably the regions harboring CKMT2 gene (creatine kinase, mitochondrial 2) and RASGRF2 gene (Ras

225 ltiplexed detection of 100 fg/ml troponin T, creatine kinase MM, and creatine kinase MB in serum.

226 The BZ protein expression of creatine kinase-mt and creatine kinase-m isoforms was si

227 Interaction between mitochondrial creatine kinase (MtCK) and adenine nucleotide translocas

228 NAME induced elevation of cardiac output and Creatine Kinase Muscle-Brain (CKMB), but had no signific

229 ts, there was a reduction in serum levels of creatine kinase muscle-brain isoenzyme, a myocardial-spe

230 Prespecified secondary outcome measures of creatine kinase, muscle strength and function, motor ner

231 s of serum cTnT, cTnI, creatine kinase (CK), creatine kinase myocardial band (CK-MB), and N-terminal

232 microg/l), and 1 equivalent to elevation of creatine kinase-myocardial band (1.5 ng/ml).

233 Creatine kinase-myocardial band (CK-MB) measurements wer

234 enrolled, 1,652 with creatine kinase and/or creatine kinase-myocardial band (CK-MB) post-procedure w

235 ention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with

236 The incidence of creatine kinase-myocardial band (CK-MB)-defined PPMI (CK

237 ethodology to assess the association between creatine kinase-myocardial band and 1-year mortality.

238 The incidence of creatine kinase-myocardial band increases >3 times the u

239 Peak post-PCI creatine kinase-myocardial band was significantly associ

240 High-sensitivity cardiac troponin T and creatine kinase-myocardial band were measured before and

241 Creatine kinase-myocardial band yielded similar results,

242 me parameter was the area under the curve of creatine kinase-myocardial brain fraction concentration.

243 The area under the creatine kinase-myocardial brain fraction curve was 3144

244 arkers included high-sensitivity troponin T, creatine kinase, myoglobin, N-terminal B-type natriureti

245 o proceeded directly to phase B for elevated creatine kinase (N = 218, with 73 randomized to ezetimib

246 h large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, prob

247 There were no differences in creatine kinase or high sensitivity C-reactive protein l

248 ted by targeted replacement of mitochondrial creatine kinase or mitochondrial-targeted CaMKII inhibit

249 Thirty-one of 34 patients had elevated creatine kinase or myoglobin.

250 at 3 months, or the area-under-the-curve for creatine kinase or troponin I.

251 95% CI 1.34, 13.71; p = 0.014), and elevated creatine kinase (OR 3.79; 95% CI 1.06, 13.51; p = 0.04),

252 nfarction </=1 flow, there was reduced serum creatine kinase (P=0.030) and a 19% reduction in cardiac

253 rapid ATP generation via the phosphocreatine-creatine kinase (PCr/CK) system, as a unique gene family

254 7 g/m(2) vs. 21 +/- 14 g/m(2); p = 0.01) and creatine kinase peak serum level (median [interquartile

255 Structural analysis of modified muscle-type creatine kinase peptide variants by two-dimensional NMR

256 letal muscle under the control of the muscle creatine kinase promoter (MCKcre mice) with mice having

257 e overexpressing PGC-1alpha under the muscle creatine kinase promoter (MPGC-1alphaTG mice) displayed

258 agged TEAD-1 under the control of the muscle creatine kinase promoter.

259 agged TEAD-1 under the control of the muscle creatine kinase promoter.

260 conversion of phosphocreatine to creatine by creatine kinase provides an essential chemical energy so

261 eatine kinase-MB (but not creatine kinase-MB/creatine kinase ratio) was higher with HBOC in moderate

262 muscle anaerobic metabolism, the rate of the creatine kinase reaction, intracellular buffering of pro

263 is replenished from phosphocreatine via the creatine kinase reaction, we have now measured the creat

264 Thus, creatine kinase reduces ADP-induced platelet activation.

265 No evidence of differences in creatine kinase release (P=0.92), troponin T (P=0.85), o

266 y (31)P nuclear MR spectroscopy, lactate and creatine kinase release spectrophotometrically, and hypo

267 e estimated by peak and area under the curve creatine kinase release was measured in all study popula

268 that the extent of infarct size measured by creatine kinase release was significantly associated wit

269 point was infarct size assessed by measuring creatine kinase release.

270 by late gadolinium enhancement sequences and creatine kinase release.

271 and increased aspartate aminotransferase and creatine kinase serum enzyme levels in cynomolgus macaqu

272 ed muscle degeneration and fibrosis, reduced creatine kinase serum levels, restored running capacity

273 This increase in creatine kinase should prompt studies examining the effe

274 Diagnosis using the classic blood marker creatine kinase sometimes yields unsatisfactory results

275 Accordingly, endogenous plasma creatine kinase, studied in 9 healthy men (mean age 27.9

276 Atorvastatin also increased average creatine kinase, suggesting that statins produce mild mu

277 but not pravastatin, induced elevated serum creatine kinase; swollen, misaligned, size-variable, and

278 apacity of oxidative phosphorylation and the creatine kinase system to buffer the cellular ATP/ADP ra

279 to examine the bioenergetic reactions of the creatine-kinase system and the ATP synthesis/hydrolysis

280 es, including aspartate aminotransferase and creatine kinase, that are typically elevated as a result

281 We assessed whether the level of plasma creatine kinase, the enzyme that utilizes ADP and phosph

282 , the characteristic clearance properties of creatine kinase, the time course of muscle fiber regener

283 intra- and intermolecular cross-links within creatine kinase, then to map the interaction surfaces be

284 sterol, low-density lipoprotein cholesterol, creatine kinase, thyroid-stimulating hormones, and eryth

285 after rest, with a concomitant reduction of creatine kinase to normal values.

286 n, stabilized the sarcolemma, restored serum creatine kinase to wild-type levels, and protected muscl

287 olipoprotein A1 (apoA1), apoE, mitochondrial creatine kinase U-type, beta-synuclein, synaptogyrin-3,

288 No individual creatine kinase value exceeded 10 times normal, but aver

289 lower limb weakness with highly raised serum creatine kinase values (average 4500 IU/l) and frequent

290 Creatine kinase values in these animals are increased an

291 Serum creatine kinase values were usually normal or slightly e

292 bout strength loss, less soreness, and lower creatine kinase values.

293 Creatine kinase was normal or mildly elevated, and muscl

294 Creatine kinase was normal or mildly elevated.

295 r beta-actin, the cytosolic brain isoform of creatine kinase was the next most abundant bundle protei

296 tions of serum transaminases, bilirubin, and creatine kinase were infrequent and similar between grou

297 ion of MyoD-target genes myogenin and muscle creatine kinase were suppressed by PAX3/FOXO1A or PAX7/F

298 erize the interaction between calmodulin and creatine kinase, which we identify as a novel calmodulin

299 tion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical

300 catalytic site of bound hexokinase or bound creatine kinase without ATP dilution in the cytosol.